ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Changing antimicrobial prescribing patterns, and laboratory reporting in Enterococcus faecalis infective endocarditis at a tertiary Australian centre.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEnterococcus faecalis (E. faecalis) infective endocarditis (EFIE) treatment consists of a penicillin backbone and a synergistic agent (gentamicin or ceftriaxone). Due to the instability of aminopenicillins in continuous infusion in the outpatient context, benzylpenicillin is used as an alternative to ampicillin, though concern regarding reduced synergy with ceftriaxone has emerged. Clinical Laboratory Standards Institute (CLSI) provides MIC breakpoints for penicillin and ampicillin. European Committee for Antimicrobial Susceptibility Testing (EUCAST) guidelines only provide breakpoints for ampicillin. We evaluated the changing antimicrobial prescribing practices, and laboratory reporting (from CLSI to EUCAST guidelines) related to EFIE treatment and outcomes at our centre.
methodsThis was a retrospective study at Monash Health, Melbourne. Adult patients aged ≥ 18 years, who were treated for EFIE from 2014 to 2022, were included. Univariable associations were evaluated (p < 0.05).
results104 patients treated for EFIE were included. Following EUCAST guideline implementation, there was a significant increase in ampicillin-based regimens prescribed as initial antimicrobials for directed EFIE therapy (64.3 to 82.3% p = 0.00135); benzylpenicillin regimens decreased across the same period (36.7% to 8.1%, p = 0.0007). In patients who received combination therapy, ceftriaxone use increased in the EUCAST period (p < 0.0001). Vancomycin prescriptions as subsequent regimen increased in the EUCAST period (0 to 19.3%, p = 0.0071). Ampicillin or benzylpenicillin monotherapy prescription as initial EFIE treatment reduced when comparing CLSI to EUCAST periods (p = 0.00001).
conclusionThere is significant heterogeneity in the antimicrobials prescribed for EFIE at our centre, reflective of evidence that emerged over the last decade, changes in susceptibility testing and reporting and lack of randomised control trial (RCT) data supporting any one regimen. RCT data is required to further inform and refine directed EFIE treatment recommendations.
Indexed as
Identifiers
41432847What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.